Janux Therapeutics (JANX) Current Leases (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Current Leases data on file, last reported at $2.5 million in Q1 2026.

• On a quarterly basis, Current Leases rose 36.5% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $2.5 million, a 36.5% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, up 36.82% from the prior year.
• Current Leases for Q1 2026 stood at $2.5 million, up from $2.4 million in the prior quarter.
• Over the last five years, Current Leases for JANX reached as high as $2.5 million in Q1 2026 and fell as low as $88000.0 in Q2 2022.
• Historically, Current Leases has averaged $1.5 million across 5 years, with a median of $1.6 million in 2024.
• Across the five-year window, Current Leases jumped 1500.0% in 2023 and climbed 14.91% in 2025, its largest moves.
• Year by year, Current Leases stood at $763000.0 in 2022, then jumped by 98.82% to $1.5 million in 2023, then advanced by 15.29% to $1.7 million in 2024, then jumped by 36.82% to $2.4 million in 2025, then advanced by 3.3% to $2.5 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $2.5 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.